Galenica AG/€GALE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Galenica AG
Galenica AG is a healthcare company based in Switzerland, with a core focus on the health and pharmacy sector. The company operates through two main segments: Health & Beauty and Services. The Health & Beauty segment includes the operation of pharmacies and the distribution of health products, while the Services segment provides logistics and related services for the Swiss healthcare sector. Founded in 1927, Galenica has evolved to become a key player in the Swiss market with a comprehensive network and infrastructure that facilitate efficient healthcare distribution. Its strategic positioning is enhanced by its extensive logistics capabilities and strong presence within Switzerland, headquartered in Bern.
Ticker
€GALE
Sector
Primary listing
XGAT
Employees
7,991
Headquarters
Bern, Switzerland
Website
Galenica AG Metrics
BasicAdvanced
€4.7B
22.75
€4.13
0.30
€2.48
1.32%
Price and volume
Market cap
€4.7B
Beta
0.3
52-week high
€96.59
52-week low
€76.19
Average daily volume
72K
Dividend rate
€2.48
Financial strength
Current ratio
1.29
Quick ratio
0.821
Long term debt to equity
48.571
Total debt to equity
57.891
Dividend payout ratio (TTM)
59.70%
Interest coverage (TTM)
16.42%
Profitability
EBITDA (TTM)
270.398
Gross margin (TTM)
11.98%
Net profit margin (TTM)
4.77%
Operating margin (TTM)
5.23%
Effective tax rate (TTM)
13.29%
Revenue per employee (TTM)
€535,180
Management effectiveness
Return on assets (TTM)
4.34%
Return on equity (TTM)
13.52%
Valuation
Price to earnings (TTM)
22.754
Price to revenue (TTM)
1.086
Price to book
3.03
Price to tangible book (TTM)
14.22
Price to free cash flow (TTM)
16.421
Free cash flow yield (TTM)
6.09%
Free cash flow per share (TTM)
5.723
Dividend yield (TTM)
2.64%
Forward dividend yield
1.32%
Growth
Revenue change (TTM)
5.91%
Earnings per share change (TTM)
8.58%
3-year revenue growth (CAGR)
2.45%
3-year earnings per share growth (CAGR)
3.80%
3-year dividend per share growth (CAGR)
3.08%
Bulls say / Bears say
Galenica reported H1 2025 adjusted EBIT of CHF 109.9 million, beating the consensus estimate of CHF 109.1 million, and raised its full-year EBIT growth guidance to 7%–9% (from 4%–6%).
For FY 2024, Galenica posted consolidated net sales of CHF 3.921 billion, representing a 4.7% year-on-year increase and outperforming the broader Swiss pharmaceutical market, highlighting solid demand.
Both core segments contributed to H1 2025 sales growth: Products & Care grew 4.6% and Logistics & IT grew 5.5%, demonstrating strong performance across Galenica’s diversified business units.
Excluding a one-off CHF 5.4 million benefit from lower-than-expected competition fines, Galenica’s H1 2025 adjusted EBIT growth was only 5.4%, indicating that the underlying operational momentum is weaker than the headline numbers suggest.
UBS Global Research downgraded Galenica to “neutral” due to planned liberalization of over-the-counter drug sales in Switzerland by 2028, which may increase competition from online retailers and put pressure on prices and revenues.
Galenica’s proposed acquisition of Labor Team is still pending approval from the Swiss Competition Commission and will be funded with short-term bridge financing, exposing the company to possible regulatory delays and integration risks before the deal closes in H2 2025.
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galenica AG stock?
Galenica AG (GALE) has a market cap of €4.7B as of September 15, 2025.
What is the P/E ratio for Galenica AG stock?
The price to earnings (P/E) ratio for Galenica AG (GALE) stock is 22.75 as of September 15, 2025.
Does Galenica AG stock pay dividends?
Yes, the Galenica AG (GALE) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €2.48158 and the yield is 1.32%. Galenica AG has a payout ratio of 59.7% on a trailing twelve-month basis.
When is the next Galenica AG dividend payment date?
The next Galenica AG (GALE) dividend payment date is unconfirmed.
What is the beta indicator for Galenica AG?
Galenica AG (GALE) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.